EFFICACY OF DEEP BRAIN STIMULATION IN OUR PATIENTS WITH PARKINSON'S DISEASE

被引:0
|
作者
Tamas, Gertrud [1 ]
Takats, Annamaria [1 ]
Radics, Peter [1 ]
Rozsa, Ildiko [1 ]
Csibri, Eva [2 ]
Rudas, Gabor [3 ]
Golopencza, Peter [4 ]
Entz, Laszlo [5 ]
Fabo, Daniel [5 ]
Eross, Lorand [5 ]
机构
[1] Semmelweis Egyet, Neurol Klin, H-1083 Budapest, Hungary
[2] Semmelweis Egyet, Pszichiatriai Klin, H-1083 Budapest, Hungary
[3] Semmelweis Egyet, MR Kutato Kozpont, H-1083 Budapest, Hungary
[4] Semmelweis Egyet, Aneszteziol & Intenziv Terapias Klin, H-1083 Budapest, Hungary
[5] Orszagos Idegtudomanyi Int, Budapest, Hungary
来源
关键词
deep brain stimulation; Parkinson's disease; efficacy; SUBTHALAMIC NUCLEUS; MEDICAL THERAPY; TRIAL;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purposes In advanced Parkinson's disease, medically refractory motor fluctuation or medically resistant tremor considerably affects quality of life. However, these symptoms can be mostly successfully treated by deep brain stimulation. We analyzed the efficacy of bilateral subthalamic stimulation in our patients with Parkinson's disease. Methods - We assessed the clinical data of ten patients who have been treated in the Department of Neurology, Semmelweis University and have been operated in the National Institute of Neurosciences between 2008 and 2011. The Hoehn-Yahr scale score, the Unified Parkinson's Disease Rating Scale score and the Parkinson's Disease Questionnaire 39, as well as the dose of antiparkinson medication were documented prior to and one year after surgery. Results - Patient condition improved according to the Hoehn-Yahr scale, approximately by Iwo stages. The dose of antiparkinson medication could be reduced by 63.4% (p=0.005) post operation. Unified Parkinson's Disease Rating Scale scores decreased by 70.9% (p=0.005). 12 hours after medication withdrawal, execution of daily activity improved by 57.1% (p<0.01) and motor functions developed by 79.1% (p<0.01). Duration of dyskinesias decreased by 62.5% (p=0.018), duration of akinesia diminished by 87.5% (p=0.005). Quality of life rose by 41.6% (p<0.01). Neuropsychological tests detected improvement in verbal memory. Conclusion - With deep brain stimulation, the dosage of antiparkinson medication could be significantly reduced, with considerable improvements in motor function and quality of life. Although the number of patients is still low, good results have been established by careful patient selection, precise neurosurgical procedure and by appropriate programming and patient care.
引用
下载
收藏
页码:115 / 120
页数:6
相关论文
共 50 条
  • [21] Deep brain stimulation for Parkinson's disease
    Lozano, AM
    PARKINSONISM & RELATED DISORDERS, 2001, 7 (03) : 199 - 203
  • [22] Deep brain stimulation in Parkinson's disease
    Kunstmann, Carolina
    Valdivia, Felipe
    De Marinis, Alejandro
    Ayach, Fredy
    Miguel Montes, Jose
    Chana-Cuevas, Pedro
    REVISTA MEDICA DE CHILE, 2018, 146 (05) : 562 - 569
  • [23] Deep Brain Stimulation in Parkinson's Disease
    Mehanna, Raja
    Fernandez, Hubert H.
    Shukla, Aparna Wagle
    Bajwa, Jawad A.
    PARKINSONS DISEASE, 2018, 2018
  • [24] Deep Brain Stimulation in Parkinson's Disease
    Malek, Naveed
    NEUROLOGY INDIA, 2019, 67 (04) : 968 - 978
  • [25] Deep brain stimulation in Parkinson's disease
    Mehanna R.
    Lai E.C.
    Translational Neurodegeneration, 2 (1)
  • [26] Deep Brain Stimulation for Parkinson's Disease
    Nikolov, Petyo
    Groiss, Stefan Jun
    Schnitzler, Alfons
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2021, 89 (01/02) : 56 - 63
  • [27] Deep Brain Stimulation for Parkinson's Disease
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1309): : 26 - 27
  • [28] Deep brain stimulation for Parkinson's disease
    Limousin, Patricia
    Martinez-Torres, Irene
    NEUROTHERAPEUTICS, 2008, 5 (02) : 309 - 319
  • [29] Deep brain stimulation for Parkinson's disease
    Herzog, J.
    Deuschl, G.
    NERVENARZT, 2010, 81 (06): : 669 - +
  • [30] Deep brain stimulation for Parkinson’s disease
    Patricia Limousin
    Irene Martinez-Torres
    Neurotherapeutics, 2008, 5 : 309 - 319